Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of oxyberberine in preparation of medicament for treating ulcerative colitis

A technology for ulcerative colitis and berberine, applied in the field of biomedicine, can solve problems such as curative effect and safety limitations, achieve anti-arrhythmic efficacy, good application prospects, and improve the effect of general symptoms

Inactive Publication Date: 2019-09-13
GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although some progress has been made in the research of the above drugs, these drugs have limitations in terms of efficacy and safety

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of oxyberberine in preparation of medicament for treating ulcerative colitis
  • Application of oxyberberine in preparation of medicament for treating ulcerative colitis
  • Application of oxyberberine in preparation of medicament for treating ulcerative colitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] The effect of embodiment 1 oxidized berberine on ulcerative colitis

[0034] 1 Experimental materials

[0035] 1.1 Experimental drugs

[0036] Berberine hydrochloride (BBR) was purchased from Chengdu Zhibiao Pure Biotechnology Co., Ltd.; oxidized berberine (OBB, self-made) (purity ≥ 98%); azathioprine (AZA) was purchased from Aspen Pharmacare Australia Pty Ltd. (Leonards, New South Wales, Australia).

[0037] 1.2 Experimental reagents

[0038] Dextran sodium sulfate (DSS, MW: 36000-50000) was purchased from MP Biomedicals, USA; the H&E staining kit was purchased from Wuhan Boster Biological Engineering Co., Ltd.; myeloperoxidase (MPO) kit was purchased from Nanjing Jiancheng Institute of Bioengineering; mouse ELISA kits: TNF-α, IL-6, IL-1β, IL-10, IL-17 and IFN-γ, purchased from Beijing Chenglin Biology; mouse IgA, IgM and IgG Elisa kits were purchased from Xinbosheng Biotechnology Co., Ltd. Antibodies JAM-A, Claudin-1, Occludin, ZO-1, ZO-2, β-actin and horseradish ...

Embodiment 2

[0088] Embodiment 2 treats the oxidized berberine medicament (tablet) of ulcerative colitis

[0089] Take 500g of oxidized berberine, add 480g of lactose and 754g of starch, mix evenly, use 7% starch slurry 350g as a binder, wet granulate, dry, add 16g of magnesium stearate, mix evenly, and press to make each tablet contain oxidized berberine. 10,000 tablets of berberine 50mg, each with a net weight of 0.21g.

[0090] Orally, for the treatment of ulcerative colitis.

[0091] Symptoms: Abdominal pain, diarrhea, blood in the stool, weight loss, etc.

Embodiment 3

[0092] Embodiment 3 treats the oxidized berberine medicament (capsule) of ulcerative colitis

[0093] Take 500g of oxidized berberine, add 980g of lactose, 1254g of starch and mix evenly, use 7% starch slurry 350g as a binder, wet granulate, dry, add 16g of magnesium stearate, mix evenly, fill to No. 1 capsule 10,000 capsules, each capsule contains 50mg of oxidized berberine, and the net weight of each capsule is 0.31g.

[0094] Orally, for the treatment of ulcerative colitis.

[0095] Symptoms: Abdominal pain, diarrhea, blood in the stool, weight loss, etc.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of oxyberberine in preparation of a medicament for treating ulcerative colitis. The research of the invention finds that: the oxyberberine can safely and effectively resist ulcerative colitis, and comprises the following effects: remarkably improving general symptoms of ulcerative colitis mice, improving pathological injury, reducing the level of colon tissue inflammatory cytokines and immunoglobulins in serum, and increasing expression of tight junction proteins (TJs) in colon tissues. The drug effect of the oxyberberine for preventing and treating the ulcerative colitis is equivalent to that of azathiopurine of a traditional first-line treatment drug, and is superior to that of berberine. In addition, the oxyberberine has high safety, and the daily application dosage of the oxyberberine is not strictly limited in terms of safety and can be adjusted according to clinical actual conditions during use, so that better curative effect is ensured. The invention provides a better new drug choice for clinically treating ulcerative colitis, and the oxyberberine has good application prospect for clinical treatment of ulcerative colitis.

Description

technical field [0001] The invention belongs to the technical field of biomedicine. More specifically, it relates to the application of oxidized berberine in the preparation of medicines for treating ulcerative colitis. Background technique [0002] Ulcerative colitis (Ulcerative colitis, UC) is a type of inflammatory bowel disease (Inflammatory Bowel Disease, IBD), listed by the World Health Organization as one of the modern refractory diseases. Traditional Chinese medicine classifies UC into categories such as "intestinal addiction", "diarrhea", and "diarrhea". UC is a nonspecific, chronic inflammatory disease of the colonic mucosa. The disease is prone to occur in young adults aged 30-40, and it is often an attack-remission-relapse pattern. The lesions of the disease involve the distal colon and rectum, and the clinical manifestations are mostly diarrhea, abdominal pain, weight loss, and blood in the stool. With the rapid modernization and westernization of people's l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61P1/00
CPCA61K31/4375A61P1/00
Inventor 苏子仁谢建辉李彩兰刘煜洪黎玉翠陈建南
Owner GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com